The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study
- PMID: 35846308
- PMCID: PMC9283682
- DOI: 10.3389/fendo.2022.922044
The Essential Role of Body Weight in Adjusting Gn Dosage to Prevent High Ovarian Response for Women With PCOS During IVF: A Retrospective Study
Abstract
Polycystic ovarian syndrome (PCOS) is the major cause of anovulatory infertility. Since women with PCOS are often accompanied by increased body weight and hyper response to controlled ovarian stimulation, individualized gonadotropin (Gn) dose is required to achieve a therapeutic effect while minimizing the risk of ovarian hyperstimulation simultaneously. We aimed to investigate the essential role of body weight in optimizing initial Gn dosage for PCOS patients during in vitro fertilization (IVF). We retrospectively included 409 infertile PCOS patients who used gonadotropin-releasing hormone (GnRH)-antagonist fixed protocol and underwent their first cycle of IVF in West China Second University Hospital from January 2019 to June 2021. Baseline characteristics controlled ovarian stimulation parameters, and reproductive outcomes were compared between patients with different body weights and different ovarian responses. Multivariable linear regression analyses were adopted to investigate the relationship between body weight and initial Gn dosage. Receiver operating characteristic (ROC) curves were drawn to find the optimal cut-off value of body weight in predicting the starting Gn dosage so as to prevent high ovarian response (HOR). We found that luteinizing hormone (LH) level and Anti-Mullerian hormone (AMH) level were lowest in the group with body weight over 70 kg and was highest in the group with body weight less than 50 kg. Increased body weight was significantly correlated to the rise of initial Gn dosage (Beta = 0.399, t = 8.921, p < 0.001). Normal ovarian response (NOR) patients had significantly less fresh cycle cancel rate and ovarian hyperstimulation syndrome (OHSS) rate which outweighed the fewer embryos compared with HOR patients. Using ROC curves, 53.25 kg (sensitivity, 84.2%; specificity, 53.8%) and 70.5 kg (sensitivity, 58.8%; specificity, 93.0%) were identified as the optimal cut-off values to predict the initial Gn dosage of no more than 150 IU and 225 IU, respectively. In conclusion, adjusting the initial Gn dosage based on body weight is crucial to preventing ovarian hyperstimulation while not influencing reproductive outcomes for PCOS patients during IVF.
Keywords: body weight; gonadotropin; in vitro fertilization; ovarian response; polycystic ovarian syndrome.
Copyright © 2022 Zeng, Chen, Zeng and Qin.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Dose Nomogram of Individualization of the Initial Follicle-Stimulating Hormone Dosage for Patients with Polycystic Ovary Syndrome Undergoing IVF/ICSI with the GnRH-Ant Protocol: A Retrospective Cohort Study.Adv Ther. 2023 Sep;40(9):3971-3985. doi: 10.1007/s12325-023-02582-2. Epub 2023 Jul 3. Adv Ther. 2023. PMID: 37395872 Free PMC article.
-
In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:46-50. doi: 10.1016/j.ejogrb.2014.05.013. Epub 2014 Jun 2. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 24965979
-
[Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].Zhonghua Fu Chan Ke Za Zhi. 2013 Nov;48(11):833-7. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24444560 Chinese.
-
Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.Sci Rep. 2022 Mar 15;12(1):4456. doi: 10.1038/s41598-022-08400-z. Sci Rep. 2022. PMID: 35292717 Free PMC article.
-
A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome.Expert Rev Endocrinol Metab. 2019 Sep;14(5):315-319. doi: 10.1080/17446651.2019.1631797. Epub 2019 Jun 26. Expert Rev Endocrinol Metab. 2019. PMID: 31242780 Review.
Cited by
-
Free Androgen Index Might Not Be a Perfect Predictor of Infertility Outcomes in Patients with Polycystic Ovary Syndrome Undergoing Frozen Embryo Transfer:A Retrospective Cohort Study.Int J Womens Health. 2024 Aug 8;16:1349-1359. doi: 10.2147/IJWH.S465541. eCollection 2024. Int J Womens Health. 2024. PMID: 39135910 Free PMC article.
-
Relationship between CCL25/CCR9 Levels in Follicular Fluid and High Ovarian Response in Patients with Polycystic Ovary Syndrome.Int J Endocrinol. 2024 Oct 3;2024:2449037. doi: 10.1155/2024/2449037. eCollection 2024. Int J Endocrinol. 2024. PMID: 39411316 Free PMC article.
-
Development and externally validated prediction model of individualization of FSH starting dose in the depot GnRH agonist protocol for the early follicular phase.Front Endocrinol (Lausanne). 2025 Mar 27;16:1542736. doi: 10.3389/fendo.2025.1542736. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40213105 Free PMC article.
-
Effect of GnRH agonist trigger with or without low-dose hCG on reproductive outcomes for PCOS women with freeze-all strategy: a propensity score matching study.Arch Gynecol Obstet. 2024 Feb;309(2):679-688. doi: 10.1007/s00404-023-07285-1. Epub 2023 Nov 30. Arch Gynecol Obstet. 2024. PMID: 38032411
-
Clinical evidence of coenzyme Q10 pretreatment for women with diminished ovarian reserve undergoing IVF/ICSI: a systematic review and meta-analysis.Ann Med. 2024 Dec;56(1):2389469. doi: 10.1080/07853890.2024.2389469. Epub 2024 Aug 12. Ann Med. 2024. PMID: 39129455 Free PMC article.
References
-
- Franks S, Hardy K. What Causes Anovulation in Polycystic Ovary Syndrome? Curr Opin Endocr Metab Res (2020) 12:59–65. doi: 10.1016/j.coemr.2020.03.001 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical